Clinical Trial Detail

NCT ID NCT02977468
Title Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT)
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Eileen Connolly
Indications

triple-receptor negative breast cancer

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.